How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma (Q38037487)

3 July 2019

title

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma (English)

1 reference

3 July 2019

1 reference

1 reference

J Wolchok

1

1 reference

3 July 2019

publication date

1 September 2012

1 reference

3 July 2019

published in

Annals of Oncology

1 reference

3 July 2019

volume

23 Suppl 8

1 reference

3 July 2019

page(s)

viii15-21

1 reference

3 July 2019

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

The Yin and Yang of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Reversal of the TCR stop signal by CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Hepatic vascular lesions associated with dacarbazine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS258

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22918923

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22918923

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

T-cell costimulation--biology, therapeutic potential, and challenges

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22918923

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDS258

1 reference

3 July 2019

PMC publication ID

6278954

1 reference

3 July 2019

PubMed publication ID

22918923

1 reference

3 July 2019